Section 35-48-2-12 - Schedule V(a) The controlled substances listed in this section are included in schedule V.(b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following quantities, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone: (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.(6) Not more than 0.5 milligrams of difenoxin (9168), and not less than 25 micrograms of atropine sulfate per dosage unit.(c) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: Pyrovalerone (1485).(d) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:(1) Brivaracetam ((2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) (2710).(2) Cenobamate ([(1R)-1- (2-chlorophenyl)-2- (tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2- (2H-tetrazol-2-yl)ethyl ester) (2720).(3) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]- carbamic acid ethyl ester] (2779).(4) Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) (2401).(5) Lacosamide [(R)-2-acetoamido-N-benzyl-3- methoxy-propionamide] (2746).(6) Lasmiditan [2,4,6-trifluoro-N- (6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide] (2790).(7) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] (2782).Amended by P.L. 48-2023,SEC. 7, eff. 7/1/2023.Amended by P.L. 10-2021,SEC. 2, eff. 7/1/2021.Amended by P.L. 61-2020,SEC. 8, eff. 7/1/2020.Amended by P.L. 119-2019,SEC. 6, eff. 7/1/2019.Amended by P.L. 283-2013, SEC. 4, eff. 7/1/2013.As added by Acts1976 , P.L. 148, SEC.7. Amended by Acts1979 , P.L. 303, SEC.7; Acts1981 , P.L. 170, SEC.6; P.L. 327-1985, SEC.3; P.L. 22-2008, SEC.5.